What Does Wall Street Think About Amicus Therapeutics (FOLD)?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best biotech stocks with high potential. On September 18, Needham analyst Gil Blum upgraded the rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD) to a Buy, setting a price target of $14.00.

Is Amicus Therapeutics, Inc. (FOLD) the Best Low Cost Stock to Buy According to Billionaires?

Similarly, Morgan Stanley analyst Maxwell Skor also maintained a Buy rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD) on September 17, setting a $12.00 price target.

The analyst consensus rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a Strong Buy, and the stock’s median price target of $8.41 implies an upside of 78.25% from current levels.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotech company that discovers, develops, and delivers medicines to treat metabolic diseases.

Its product portfolio includes the first and only approved oral precision medicine to treat Fabry disease, a clinical-stage treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

While we acknowledge the potential of FOLD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than FOLD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.